AR051829A1 - Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia - Google Patents

Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia

Info

Publication number
AR051829A1
AR051829A1 ARP050104492A ARP050104492A AR051829A1 AR 051829 A1 AR051829 A1 AR 051829A1 AR P050104492 A ARP050104492 A AR P050104492A AR P050104492 A ARP050104492 A AR P050104492A AR 051829 A1 AR051829 A1 AR 051829A1
Authority
AR
Argentina
Prior art keywords
short
interference
arn
compositions
methods
Prior art date
Application number
ARP050104492A
Other languages
English (en)
Original Assignee
Schering Corp
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Canji Inc filed Critical Schering Corp
Publication of AR051829A1 publication Critical patent/AR051829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente suministra ácidos nucleicos cortos e interferencia, ya sean de hebra simple o de doble hebra que provocan la degradacion del ARNm inducida por el ARNi a partir del gen de la cadena de sodio de Nav1.8; a las composiciones farmacéuticas que comprenden tales ácidos nucleicos cortos de interferencia; vectores recombinantes que comprenden tales ácidos nucleicos cortos de interferencia; un método para inhibir la traduccion de un ARNm; un método para inhibir la expresion de un polipéptido; un método para bloquear el potencial de la membrana en una célula; un método para bloquear la corriente de sodio dentro de una célula; y un método para inhibir el dolor cronico.
ARP050104492A 2004-10-27 2005-10-26 Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia AR051829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62248404P 2004-10-27 2004-10-27

Publications (1)

Publication Number Publication Date
AR051829A1 true AR051829A1 (es) 2007-02-14

Family

ID=36061603

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104492A AR051829A1 (es) 2004-10-27 2005-10-26 Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia

Country Status (14)

Country Link
US (4) US7786291B2 (es)
EP (2) EP1809745A2 (es)
JP (3) JP2008517629A (es)
KR (1) KR20070083828A (es)
CN (2) CN102352355A (es)
AR (1) AR051829A1 (es)
AU (1) AU2005299310A1 (es)
CA (1) CA2584785A1 (es)
IL (1) IL182680A0 (es)
MX (1) MX2007005069A (es)
NO (1) NO20072692L (es)
SG (1) SG158921A1 (es)
WO (1) WO2006047687A2 (es)
ZA (1) ZA200703453B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056326A2 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
UA106724C2 (uk) 2008-06-30 2014-10-10 Янссен Фармацевтика Нв Спосіб отримання заміщених піримідинових похідних
SG11201401032YA (en) * 2011-10-26 2014-07-30 Pfizer Ltd (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
TWI516593B (zh) * 2012-06-11 2016-01-11 義守大學 一種聚核苷酸用以製備減緩疼痛藥物之用途
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN113041451B (zh) * 2015-05-11 2023-06-09 亚克安娜治疗学有限公司 药物输送系统和方法
KR20190098131A (ko) 2016-12-21 2019-08-21 알시온 라이프사이언스 인크. 약물 전달 시스템 및 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513180D0 (en) * 1995-06-28 1995-08-30 Univ London Ion channel
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
IL151928A0 (en) * 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
ES2215494T5 (es) * 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US20060030534A1 (en) * 2002-09-04 2006-02-09 Gabriele Dorn Treatment of neurological disorders by dsrna administration
WO2004087956A2 (en) * 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Cell lines for the functional expression of nav1.8
DK3604537T3 (da) * 2003-06-13 2022-02-28 Alnylam Europe Ag Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
US7341835B2 (en) * 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse

Also Published As

Publication number Publication date
CN101103112A (zh) 2008-01-09
EP2371954A1 (en) 2011-10-05
IL182680A0 (en) 2007-09-20
NO20072692L (no) 2007-05-25
EP1809745A2 (en) 2007-07-25
US8309703B2 (en) 2012-11-13
WO2006047687A2 (en) 2006-05-04
JP2011015695A (ja) 2011-01-27
JP2008517629A (ja) 2008-05-29
JP2013176386A (ja) 2013-09-09
CN101103112B (zh) 2011-11-16
KR20070083828A (ko) 2007-08-24
ZA200703453B (en) 2008-06-25
US20130109739A1 (en) 2013-05-02
US20060199779A1 (en) 2006-09-07
WO2006047687A3 (en) 2006-07-06
MX2007005069A (es) 2007-06-25
AU2005299310A1 (en) 2006-05-04
US20100305192A1 (en) 2010-12-02
CN102352355A (zh) 2012-02-15
US7786291B2 (en) 2010-08-31
SG158921A1 (en) 2010-02-26
US8729045B2 (en) 2014-05-20
US20140256787A1 (en) 2014-09-11
CA2584785A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AR051829A1 (es) Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia
Uchida et al. Neuron-restrictive silencer factor causes epigenetic silencing of Kv4. 3 gene after peripheral nerve injury
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
EA202191313A1 (ru) Композиции на основе липидных наночастиц
CO2017009083A2 (es) Arni dirigido a la proteína hungtingtina, partículas víricas que lo contienen y métodos para reducir la toxicicidad del arni
CL2016003041A1 (es) Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014.
AR062336A1 (es) Recombinacion de homologos mediada por nucleasas en dedo de zinc
ES2509890T3 (es) Sustancias y composiciones para potenciar la reparación de ADN y procedimientos de uso
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
AR050211A1 (es) Composiciones y metodos que usan interferencia de arn para el control de nematodos
BR112017018383A2 (pt) inclusão de éxon2 induzida por anti-sentido em alfa-glucosidase ácida
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CL2021003169A1 (es) Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas
EA201391331A1 (ru) Активные и селективные ингибиторы nav1.3 и nav1.7
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
CL2022000040A1 (es) Composición farmacéutica que comprende un compuesto de tetrahidropirazolopirimidinona
AR079649A1 (es) Composiciones y metodos para inhibir la expresion de genes il-18
AR078921A1 (es) Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno

Legal Events

Date Code Title Description
FA Abandonment or withdrawal